Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy.

Cancer

Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Published: January 2020

Hematopoietic stem cell transplantation (HCT) has been an integral component in the treatment of many hematologic malignancies. Since the development of HCT nearly 50 years ago, the role of this modality has evolved as newer treatment approaches have been developed and integrated into the standard of care. In the last decade, novel and highly active targeted therapies and immunotherapies have been approved for many hematologic malignancies, raising the question of whether HCT continues to retain its prominent role in the treatment paradigms of various hematologic malignancies. In this review, the authors have described the current role of autologous and allogeneic HCT in the treatment of patients with acute leukemias, aggressive B-cell lymphomas, and multiple myeloma and discussed how novel targeted therapies and immunotherapies have changed the potential need, timing, and goal of HCT in patients with these diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32659DOI Listing

Publication Analysis

Top Keywords

hematologic malignancies
12
hematopoietic stem
8
stem cell
8
cell transplantation
8
targeted therapies
8
therapies immunotherapies
8
hct
5
transplantation blood
4
blood cancers
4
cancers era
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!